07 Aug Ovarian Cancer: Proteomics Study Allows Identification of Subtype Resistant to Chemotherapy
Posted at 14:18h
in Author Interviews, Biomarkers, Cancer Research, Genetic Research, Ovarian Cancer
MedicalResearch.com Interview with:
Pei Wang, PhD
Professor, Department of Genetics and Genomic Sciences
Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Michael J. Birrer MD PhD
Director, Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
Little Rock, AR 72205
Amanda G. Paulovich MD PhD
Translational Science and Therapeutics Division
Fred Hutchinson Cancer Center
Seattle WA 98109
MedicalResearch.com: What is the background for this study? How common is serous ovarian cancer?
Response: Epithelial ovarian cancer accounts for >185,000 deaths/year worldwide. The most common subtype, high-grade serous ovarian cancer (HGSOC), accounts for 60% of deaths. Despite improvements in surgical and chemotherapeutic approaches, HGSOC mortality has not changed in decades. Five-year survival remains ~30% for the majority of patients.
Standard of care involves surgical debulking combined with adjuvant or neoadjuvant chemotherapy with carbo- or cisplatin in combination with a taxane. At diagnosis, HGSOC is among the most chemo-sensitive of all epithelial malignancies, with initial response rates of ~85%, presumably related to DNA repair defects. Platinum is thought primarily to drive the response rate, due to the lower single-agent response rate for taxanes.
Unfortunately, 10-20% of HGSOC patients have treatment-refractory disease at diagnosis, fail to respond to initial chemotherapy, and have a dismal prognosis. The poor response to subsequent therapy and median overall survival of ~12 months for these patients has not changed in 40 years.
Despite >30 years of literature studying platinum resistance in cancer, there currently is no way to distinguish refractory from sensitive HGSOCs prior to therapy. Consequently, patients with refractory disease experience the toxicity of platinum-based chemotherapy without benefit. Due to their rapid progression, they are commonly excluded from participating in clinical trials. Consequently, there is no ongoing clinical research that could identify effective therapeutic agents for these patients or provide insights into molecular mechanisms of refractory disease. “Right now, we can’t identify drug-resistant ovarian cancer patients up front,” said co-senior author Michael Birrer, MD, PhD, who directs UAMS’ Winthrop J. Rockefeller Cancer Institute. “We find them by default: They get sick and pass away so quickly that they can’t even be put on new clinical trials.”
To address this unmet clinical need, we performed proteogenomic analysis of treatment-naïve HGSOCs (chemo-sensitive and chemo-refractory) to identify molecular signatures of refractory HGSOC and to identify potential treatment targets.
Lone Star Tick Nymph-CDC image[/caption]
MedicalResearch.com: What is the background for this study? Would you briefly describe Alpha-gal Syndrome?
Response: Alpha-gal syndrome is an emerging and potentially life-threatening allergic condition that is associated with a tick bite. It is also called alpha-gal allergy, red meat allergy, or tick bite meat allergy.
Increasing case studies and anecdotal reports suggested that AGS was a growing concern, but, prior to these studies, information on clinician awareness and the number of people impacted was not available at a national level.

Mytien Nguyen[/caption]
Mytien Nguyen, MS
Department of Immunobiology,
Yale School of Medicine
New Haven, Connecticut
MedicalResearch.com: What is the background for this study?
Response: Physician-scientists are critical for innovative translational research.
Dr. Li Li[/caption]
Li Li, M.D., Ph.D., M.P.H
Walter M. Seward Professor
Chair of Family Medicine
Director of population health
University of Virginia School of Medicine
Editor-in-chief of The BMJ Family Medicine
Dr. Li joined the U.S. Preventive Services Task Force in January 2021
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The Task Force reviewed the latest available evidence to evaluate whether screening all children and adolescents who are 20 years old or younger for high cholesterol improves their heart health into adulthood.
At this time, there is not enough evidence to determine whether or not screening all kids is beneficial, so we are calling for additional research on the effectiveness of screening and treatment of high cholesterol in kids and teens.
Dr. Callaghan[/caption]
Bridget Callaghan Ph.D.
Assistant Professor of Psychology
UCLA
Dr. Callahan studies interactions between mental and physical health across development.
MedicalResearch.com: What is the background for this study?
Response: A growing body of evidence links the gut microbiome to brain and immune functioning, and changes to that community of microorganisms is likely among the ways that hardship affects children’s socioemotional development.
Limited evidence in humans has demonstrated the adversities experienced prenatally and during early life influence the composition of the gut microbiome, but no studies had examined whether stress experienced in a mother's own childhood could influence the microbiome of the next generation of children.
Kazi Albab Hussain[/caption]
Kazi Albab Hussain
Graduate Student (PhD)
Specialization: Water Resources
Advisor: Professor Yusong Li, PhD
Associate Dean for Faculty and Inclusion
MedicalResearch.com: What is the background for this study?
Response: Microplastics have been detected in various food items and beverages, including table salt, bottled water, fish, and mussels. The extensive use of plastic-based products in food preparation, storage, and handling has raised concerns about the direct release of microplastics. Interestingly, we often discuss microplastics but overlook nanoplastics in the conversation. Due to their smaller size, nanoplastics are harder to be detected.
In our study, we wanted to see the release of both microplastics and nanoplastics, as nanoplastics may be even more toxic than microplastics.
Unfortunately, infants and toddlers are particularly vulnerable to the potential health impacts of micro- and nanoplastics. Studies have shown significant ingestion of these particles from polypropylene feeding bottles and silicone-rubber baby teats. We aimed to investigate the release of of micro- and nanoplastics, estimated their exposure for infants and toddlers, and evaluated their cytotoxicity to human embryonic kidney cells.
MedicalResearch.com: What is the background for this study?
Response: I became interested in dog's sense of smell several years ago while doing therapy dog demonstrations at the California Science Center in Los Angeles during a special traveling exhibit "Dogs! A Science Tail." (Now at the Orlando Science Center). I did a lot of research on this topic and taught children about it through the Los Angeles Public Library using my Great Pyrenees therapy dogs. Then, COVID broke out and I expanded my research into any work being done to possibly utilize scent dogs for screening and testing for COVID. I found only a few such studies. However, I fortuitously met Heather Junqueira of BioScent, Inc. (in Florida) online and she was beginning to successfully teach her beagles to detect COVID-related odors. She agreed to co-author a peer-reviewed review paper with me. That led to our first paper -
Dickey, T, Junqueira, H. Toward the use of medical scent dogs for COVID-19 screening. J Osteopath Med 2021;1(2): 141-148.
Dr. Davis[/caption]
Prof. Jonathan Davis, MD,
Chief of Newborn Medicine
Tufts Medical Center and
[caption id="attachment_60599" align="alignleft" width="125"]
Dr. Kruger[/caption]
Jessica Kruger PhD
Clinical Associate Professor of Community Health and Health Behavior
University at Buffalo School of Public Health and Health Professions
MedicalResearch.com: What is the background for this study?
Response: The 2018 Farm Bill authorizing hemp production led to new cannabinoids in the consumer marketplace. As the market becomes increasingly saturated with suppliers, companies continually diversify available products.
The rapid emergence of novel cannabinoids outpaces systematic research necessary to inform regulations and harm reduction. Empirical evidence is needed to guide policies, practices, and education of consumers. Product manufacturers, social media participants, and cannabis oriented on-line news sources have claimed that THC-O-acetate is a "psychedelic" cannabinoid, producing experiences similar to those associated with LSD, psilocybin, mescaline, and DMT.
Dr. Potnuru[/caption]
Paul Potnuru, MD
Assistant Professor
Anesthesiology, Critical Care and Pain Medicine
The John P. and Kathrine G. McGovern Medical School
The University of Texas Health Science Center at Houston
Dr. Fink[/caption]
Dorothy A. Fink, MD
Deputy Assistant Secretary for Women's Health
Director, Office on Women's Health
US Department of Health & Human Services
Rockville, MD
MedicalResearch.com: What is the background for this study?
Response: Delivery-related mortality in U.S. hospitals has decreased for all racial and ethnic groups, age groups, and modes of delivery while the prevalence of severe maternal mortality (SMM) increased for all patients, with higher rates for racial and ethnic minority patients of any age.
This study specifically looked at inpatient delivery-related outcomes and found a 57% decrease from 2008-2021. The decreasing mortality rates within the inpatient delivery setting demonstrated as statistically significant and a welcome finding for all women.
This study also looked with greater granularity at the impact of race, ethnicity, and age. Mortality for American Indian women decreased 92%, Asian women decreased 73%, Black women decreased 76%, Hispanic women decreased 60%, Pacific Islander women decreased 79%, and White women decreased 40% during the study period.
Valentina Paz[/caption]
Valentina Paz, M.Sc
Dr. Ogedegbe[/caption]
Gbenga Ogedegbe, MD, MPH
Dr. Adolph & Margaret Berger Professor of Population Health
Director, Division of Health & Behavior
Director Center for Healthful Behavior Change
Department of Population Health
NYU Langone Health
NYU School of Medicine
Member of the